Prevention of Heart Damage During Anthracycline Cancer Chemotherapy

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1145776

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Doxorubicin is an effective medicine widely used for the treatment of cancer. However, it can cause heart damage, which not only creates a new health problem, but also limits the length of doxorubicin treatment cancer patients can receive, and therefore the likelihood of cancer cure. Preventing heart damage by doxorubicin is therefore important to improve overall cancer cure rates and patient health. This study aims to develop new medications to prevent heart damage during cancer chemotherapy.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2020

Funding Scheme: Project Grants

Funding Amount: $327,214.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Toxicology (incl. Clinical Toxicology)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

animal model | cancer chemotherapeutic agents | cardioprotection | drug toxicity | xenografts

Related Links